EU Portal and Database



Similar documents
The EU Clinical Trial Regulation A regulator s perspective

The Clinical Trials Regulation EU No 536/2014: and Phase I trials

The EU portal and database

Clinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010

The New EU Clinical Trial Regulation Potential Impacts on Sites

ICRIN Seminar on EU Regulation of Clinical Trials

White Paper The EU Clinical Trials Regulation Main Changes and Challenges

Clinical research: where are we with the new (Paediatric) RC trial Regulation

EFPIA Principles for the Development of the EU Clinical Trials Portal and Database

The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly

Clinical trials regulation

Biotech Concerto #3. European Clinical Trial Environment

EMA Update Clinical Trials

Guideline on good pharmacovigilance practices (GVP)

The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation

EU PAS Register Guide

Regulation of clinical trials with medicinal products: Where are we now?

Agence fédérale des médicaments et des produits de santé

Post-authorisation safety studies and the EU PAS Register

EU Clinical Trials Regulation Regulation EU 536/2014

Clinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation

Clinical trials in developing countries submitted to EMEA for regulatory purposes

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Russia

EudraVigilance stakeholder change management plan

Implementation strategy for ISO IDMP in EU

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

Date : Date of start of procedure: Authorisation/ positive opinion :

PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING

Questions & answers on signal management

Strong support. Remaining concerns

Guideline on good pharmacovigilance practices (GVP)

The EMA current activities towards ISO IDMP implementation

Guideline on good pharmacovigilance practices (GVP)

LEBANESE MINISTRY OF HEALTH DIRECTIVE

The European regulatory system for medicines and the European Medicines Agency

Resources Based, Manufacturing and Consumer Goods Industries Chemicals Industry

Quick Response (QR) codes in the labelling and package leaflet of centrally authorised 1 medicinal products

GCP Inspection of Ti Trial Master Files

Wissenschaftliche Prüfungsarbeit. zur Erlangung des Titels. Master of Drug Regulatory Affairs

This is meant to be a narrative rather than a critical summary I have a lot of questions about the proposal but I will look into these separately.

The new European clinical trials regulation Dr. N.Gökbuget

Early Phase Clinical Trials: Public Access to the EU Database Repository

Questions and Answers to the Annual Safety Report

Guideline on good pharmacovigilance practices (GVP)

EU Clinical Trials Register. An agency of the European Union

What is necessary to provide good clinical data for a clinical trial?

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies

Pharmacovigilance System Master File (PSMF), QPPV and audits

A 4.5 Validity Period of a Marketing Authorisation

Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals

The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010

A critical review of the current. marketing authorisation transfer procedure. in Europe

Response of the German Medical Association

Federal agency for medicines and health products

Oversight of Clinical Trials in Europe - Member State perspective. Gunnar Danielsson Senior Expert Pharmaceutical Inspector

COMMISSION REGULATION (EU)

Serious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Norway

GCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS

EBA/RTS/2016/ January Final Report

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

The Quality System for Drugs in Germany

Detailed guidance on the European clinical trials database (EUDRACT Database)

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark

Update: Proposed Medical Device Regulation (MDR) & IVD Regulation (IVDR)

HSE: Frequently Asked Questions

Adoption by GCP Inspectors Working Group for consultation 14 June End of consultation (deadline for comments) 15 February 2012

EDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond

UK Implementation of the EU Clinical Trial Directive 2001/20/EC:

College ter Beoordeling van Geneesmiddelen

COMMISSION DIRECTIVE 2003/94/EC

Template for essential information to be provided for proposals including clinical trials / studies / investigations

The new EU Clinical Trials Regulation How NHS research and patients will benefit

Standard operating procedure

GRANT AGREEMENT FOR STUDIES ERASMUS

RECOMMENDATION 2013/473/EU ON NOTIFIED BODIES AUDITS

EBA FINAL draft Regulatory Technical Standards

Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015

Work plan for GMP/GDP Inspectors Working Group for 2016

Comparison of EU-Pharmacovigilance System Master File (PSMF) with US System

Overview of Key Obligations Under Regulation (EC) No. 1272/2008 on the Classification, Labelling and Packaging of Substances and Mixtures (CLP)

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity

Fourth Railway Package proposed by the European Commission

Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009

GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP)

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager

Guidance on the In Vitro Diagnostic Medical Devices Directive 98/79/EC

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2012) Sweden

20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/F2/BL D(2003) CT 1 Revision 2

EUROPEAN MEDICINES PRACTICES AND TOOLS AGENCY DRUG SAFETY

Consultation Paper. ESMA Guidelines on Alternative Performance Measures. 13 February 2014 ESMA/2014/175

RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2012) Germany

Transcription:

Berlin Bonn European Legislation: The New Regulation on Clinical Trials on Medicinal Products for Human Use EU Portal and Database 1 1. EU CT Regulation Scope, History, Entry into Force 2. (General) Legal Basis, Setting up and Maintenance Working Groups:, EC, EMA (Stakeholder) 3. (Details) Functional Specifications to be Audited EU Portal and other Systems User Registration and User Rights 4. Summary 2

EU CT Regulation Scope REGULATION (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Applies on all clinical trials conducted in the EU N0T on non-interventional clinical studies 3 EU CT Regulation History 17.07.2012 Regulation Proposal made by EC 24.07.2012 Start of Negotiations in the Council in Brussels 09 / 2012 Hearing in Germany in the Ministry 01 / 2013 Decision of German Bundestag (BT Drs 17/12183) 29.05.2013 Voting in ENVI Committee of EP >900 Amendments 20.12.2013 Agreement of Council, EP and Commission on a joint position to the Regulation Proposal (informal trialogue) 02.04.2014 Voting in Plenum of the EP, Approval of ENVI on 22.01.14 14.04.2014 Formal Adoption of the Council 27.05.2014 Publication in the Official Journal of the EU 16.06.2014 Entry into Force 4

EU CT Regulation Enty into Force, Transition Periods (Examples using fictious Dates) 27. May 2014 Publication Entry into Force 16. June 2014 Application of the new EU-Regulation 1. March 2017 Application of the new EU-Regulation for all CT 1. March 2020 Verification of the Functionality 1. August 2016 At least 6 months prior to application Functionality needs to be confirmed. Audit 1 February 2016 2 years Transition Period: Option EU-Regulation / Directive 2001/20/EC 1. March 2018 3 years Transition Period: CT-application before Application of EU-Regulation 1. March 2017 5 1. EU CT Regulation Scope, History, Entry into Force 2. (General) Legal Basis, Transparency rules, Setting up and Maintenance Working Groups:, EC, EMA (Stakeholder) 3. (Details) Functional Specifications to be Audited EU Portal and other Systems User Registration and User Rights 4. Summary 6

Legal Basis The EMA shall, in collaboration with the and the EC set up and maintain an EU portal & database. (Regulation (EU) No 536/2014, Articles 80, 81) 7 Transparency The EU database shall be publicly accessible unless, for all or part of the data and information contained therein, confidentiality is justified on any of the following grounds (Regulation (EU) No 536/2014, Articles 80, 81): Protecting personal data Protecting commercially confidential information Protection confidential communication between Ensuring effective supervision 8

CT Application and Approval Process Future Situation Current Situation Database EudraCT 1-5 Affiliate SPON- SOR Aff- 2 Aff- 3 EU-Portal NCA- 1 R NCA -2 NCA -3 EudraCT Aff- 1 Aff- 6 SP Aff- 5 Aff- 4 NCA -6 NCA -4 NCA -5 9 Working Groups Expert Group to work on a concept functional specifications to be audited : (and Ethic Committee) (BE, CZ, DE, IR, NL, ES, SE, UK, EC, EMA) Subgroups to work on details A Data fields, forms B Structure and content of the application dossier (Sponsor driven activities) C Process flow (application, validation, evaluation, authorisation) ( driven activities) D Metadata search and reporting E User roles and access rights (User management and other requirements) F System and reporting G Inspections (Inspections) H Safety reporting Group All : Information/adoption of proposals drafted by the Expert Group EU Portal and Database Stakeholder Meetings: organisations invited by EMA 10

1. EU CT Regulation Scope, History, Entry into Force 2. (General) Legal Basis, Transparency rules, Setting up and Maintenance Working Groups:, EC, EMA (Stakeholder) 3. (Details) Functional Specifications to be Audited EU Portal and other Systems User Registration, Administration and User Rights 4. Summary 11 Functional Specifications 12

Functional specifications high level business requirements The functional specifications are to describe the high level requirements for the EU portal and database. An Addendum to the functional specifications for defining transparency rules was added. These will be the basis for the audit of the EU portal and database. In parallel, the detailed business requirements that will enable the preparation of the use cases will be collected. Open issues: details transparency rules, project safety reporting. 13 Scope of Functional Specifications and Audit Source EMA 14

Additional Requirements to be made available in the Workspace (not to be audited) 1. Communication features for general discussion 2. Exchange of documents and data between systems and EU system 3. Links to CT systems allowing a full range of statistics 4. Delegation of the R role to another 5. Initiation of an ad hoc-workflow/case management for assessment of CT related issues (e.g. safety) 6. Cooperation in assessment and surveillance of safety 7. Link to EudraVigilance database 8. Uploading of CT dossiers prepared outside of the workspace 15 Project Safety Reporting Upgrade of the Eudra Vigilance CT Modules Creation of an e-web based form for the reporting of SUSARs Development of an Annual Safety Report (ASR) Repository Add a functionality to allow the forwarding of SUSARs and ASRs to the Source EMA 16

: Functional Specifications Annex 2 (Submission through the EU Portal) Work Activities 17 Access Single log in to access workspace and other systems (DWH, EV CTM, ASR repository) and in order to submit to the database through the EU Portal All users will need to be registered in the EMA systems before they can access the. A user name and password will be provided to access the system. Access to the Portal functions will be provided according to user s role. The system will display the appropriate data to users and make available the appropriate activities to be executed according to the user s role in the system. 18

Involved Parties in Germany Bundesoberbehoerden: BfArM, PEI Ethic Committees Laender : Inspectorates 19 Users I Marketing Authorisation Holder To upload and submit the CT reports. To manage MAH Users. European Commission (EC) To upload and submit the Union control reports. To manage EC Users. 20

Users II Sponsor To prepare and submit applications, notifications and responses to requests for additional information. To manage Sponsor Users. To monitor the work flow of the CT. To prepare and submit the assessment feedback (validation, assessment, decision, answer to questions of ). To monitor the work flow of the CT. To collaborate between (for multi state application). To communicate with sponsor and between. To manage Users. To supervise the CT through out it s life cycle. 21 User Structure Proposed Relationship between Users EMA Administrator EMA User Trial Primary User Super User EC User Sponsor User 1 Sponsor User 2 Sponsor User 3 Administrator User high level User low level Work packages (examples) Source EMA User 1 read/upload dossier part 1 upload/submit report User 2 User 3 User 4 read/upload all data upload/submit safety reporting User 5 22

Super User I Super User (authority) define their super user Maintain full rights for all activities from EMA Admin; rights are transferable to another user (Back-Up) -consolidation of work packages for users- Access to all documents related to part I, for all C regardless whether they are R or C Super User (Sponsor/MAH) System allocated and registered upper user automatically during the submission procedure of CT Maintain full rights for submitted CT; rights are transferable to other users of this CT -consolidation of work packages- 23 Super User II (Work Packages) consolidate allocate CT 1 Super-User EU CT number Application Substance Start / End Work Package 1 User 1 Patients UE/SUSAR Modifications Work Package 2 User 2 3rd countries Source: BH, BPI, vfa Results Work Package 3 User 3 24

Initial Registration for a new User User has no link to sponsor or authority. User has to register himself in the system. User has no link to sponsor or authority. User will be assigned automatically to sponsor/super user with all rights. Super user can delegate activities for one or for all general tasks for all CT. SP User submits the CT dossier. Pre defined super user can assign registered users of the authority for CT conducted in his Source: BAH, BPI, vfa can validated the identity of the sponsor (users) 25 Summary I Set up and maintained in collaboration with EMA, EC and Publicly accessible but protecting personal data, commercially confidential information, confidential communication between and ensuring effective supervision Requirements to be audited are described in document Functional Specifications with addendum describing transparency rules Additional requirements (not to be audited) will be made available in the workspace 26

Summary II Single log in to access workspace, EU database and other systems; access to portal functions will be provided according to user s role Application procedure and user registration are separate procedures and independently For registration each user must be assigned to an organization, which is known by the portal User management is using the principle of super user Planned verification of functionality in August 2016 27 Thank you very much for you attention! 28 28

Information related to Clinical Trials http://ec.europa.eu = European Commission http://www.ema.europa.eu = European Medicines Agency http://www.hma.eu = (National) Medicines Authorities in the European Union http://www.bmg.de = 29